Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
CSIMC Subcommittee Agrees on Introduction of New Price-Cut Rule for Long-Listed Products
The Central Social Insurance Medical Council’s (CSIMC) Expert Subcommittee on NHI Drug Pricing Affairs on December 5 agreed on the introduction of a new rule to cut the prices of long-listed products for which the shift to generics is deemed…
To read the full story
Related Article
- Long-Listed Products Not Granted Premium Should Be Exempted from New Rule: FPMAJ’s Kamoya
December 10, 2012
- Expert Subcommittee to Discuss New Targets for Generic Drugs at Next Meeting
November 30, 2012
- FPMAJ Chairman Naito Nudges CSIMC to Discuss Perpetuation of Premiums, Abolishment of Special Price Cuts for Long-Listed Drugs
November 29, 2012
- CSIMC Subcommittee Eyes Price Cuts for Long-Listed Drugs with Slow Generic Penetration
November 16, 2012
REGULATORY
- Japan Enacts Revised Immunization Act, Opens Way for RSV Antibodies under NIP
July 27, 2026
- PMDA Sees Drop in Japan-China Bilateral Regulatory Exchanges
July 27, 2026
- MHLW to Hear Patient Groups on OTC-Like Drug Charge Exemptions
July 27, 2026
- Japan to Clarify Non-Clinical Data Waivers for Repurposed Drugs, Ease Sakigake Rules
July 24, 2026
- Share of Negative-Margin WPPs Rises to 6.9%, Wholesalers Cite Communication Gap
July 24, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…